Relx NV : Trading opportunity
Entry price | Target | Stop-loss | Potential |
---|
€14.95 |
€0 |
€14.3 |
-100% |
---|
Reed Elsevier could regain its upward trend after having run out of steam.
According to Surperformance ratings, the group has strong fundamentals, both in terms of business predictability and valuation. In addition, analysts have recently revised upward their earnings estimates and now expect a profit of EUR 0.77 per share for the current year.
Following a bullish wave, the stock now shows a slight decline has lead the share towards its EUR 14.7 medium-term support. On this level, remobilization of buyer flows would allow an uptrend in the medium and long term.
In this configuration, a rebound seems unavoidable in the EUR 14.7 area. Investors could take a buy order on this level and get a good entry point with a stop below the medium term support. Objectives will be fixed first at EUR 15.25 and then EUR 15.8.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.